The systemic lupus erythematosus (SLE) treatment pipeline is experiencing unprecedented expansion, driven by increasing disease awareness, rising pre ...

Although it did not meet the primary endpoint of dose-response relationship, when compared to placebo, enpatoran demonstrated improvements in measures of both systemic and cutaneous disease activity ...

Researchers have found in a recent meta-analysis that belimumab is more effective than placebo in treating systemic lupus erythematosus (SLE), based on BICLA criteria. This finding ...

Flare and persistently active disease are prevalent in a multinational cohort study of patients with systemic lupus erythematosus, with some having persistently active disease without flare.

Magnetic resonance imaging (MRI) findings such as inflammatory-type lesions and myelopathies are significantly associated with attribution of neuropsychiatric (NP) events to systemic lupus ...

Enpatoran is a selective Toll-like receptor (TLR)7/8 inhibitor under investigation for the treatment of systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). By inhibiting ...

Six of the patients, of whom four had non-renal SLE, had follow-up of at least 24 weeks. Of those, five showed dramatic ...

BARCELONA -- A novel antibody-based drug targeting the CD40 ligand helped close to half of patients with treatment-refractory systemic lupus erythematosus (SLE) get symptoms under control, according ...

The American College of Rheumatology (ACR) has released a summary of a guideline with updated recommendations for the treatment of systemic lupus erythematosus (SLE). The previous guideline for ...

Full results from the first phase 3 trial of UCB and Biogen's anti-CD40L antibody dapirolizumab pegol (DZP) in systemic lupus ...